Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer. (Q27853084)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer.	scientific article

Statements

scholarly article

1 reference

PubMed publication ID

13 November 2016

Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer. (English)

1 reference

PubMed publication ID

13 November 2016

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

ChEBI release 2020-05-28

colorectal carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

H S Hochster

1

0 references

N Uboha

2

0 references

W Messersmith

3

0 references

P J Gold

4

0 references

B H ONeil

5

0 references

D Cohen

6

0 references

C Denlinger

7

0 references

S Cohen

8

0 references

C G Leichman

9

0 references

L Leichman

10

0 references

H-J Lenz

11

0 references

publication date

January 2015

0 references

Cancer Chemotherapy and Pharmacology

0 references

75

0 references

1

0 references

17-23

0 references

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2609-3

21 January 2018

Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2609-3

21 January 2018

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2609-3

21 January 2018

BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2609-3

21 January 2018

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2609-3

21 January 2018

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2609-3

21 January 2018

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2609-3

21 January 2018

Ras oncogenes and their downstream targets

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2609-3

21 January 2018

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2609-3

21 January 2018

Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2609-3

21 January 2018

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2609-3

21 January 2018

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2609-3

21 January 2018

The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2609-3

21 January 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2609-3

21 January 2018

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2609-3

21 January 2018

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2609-3

21 January 2018

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2609-3

21 January 2018

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2609-3

21 January 2018

MEK inhibitors: a patent review 2008 - 2010.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2609-3

21 January 2018

Improved survival with MEK inhibition in BRAF-mutated melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2609-3

21 January 2018

PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2609-3

21 January 2018

Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2609-3

21 January 2018

Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2609-3

21 January 2018

Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2609-3

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27853084&oldid=2177418226"